Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period
King, J. P.; Chung, J. R.; Donahue, J. G.; Martin, E. T.; Leis, A. M.; Monto, A.; Gaglani, M.; Dunnigan, K.; Raiyani, C.; Saydeh, S.; Flannery, B.; Belongia, E. A.
Show abstract
BackgroundSymptoms of COVID-19 including fatigue and dyspnea, may persist for weeks to months after SARS-CoV-2 infection. This study compared self-reported disability among SARS-CoV-2-positive and negative persons with mild to moderate COVID-19-like illness who presented for outpatient care before widespread COVID-19 vaccination. MethodsUnvaccinated adults with COVID-19-like illness enrolled within 10 days of illness onset at three US Flu Vaccine Effectiveness Network sites were tested for SARS-CoV-2 by molecular assay. Enrollees completed an enrollment questionnaire and two follow-up surveys (7-24 days and 2-7 months after illness onset) online or by phone to assess illness characteristics and health status. The second follow-up survey included questions measuring global health, physical function, fatigue, and dyspnea. Scores in the four domains were compared by participants SARS-CoV-2 test results in univariate analysis and multivariable Gamma regression. ResultsDuring September 22, 2020 - February 13, 2021, 2,712 eligible adults were enrolled, 1,541 completed the first follow-up survey, and 650 completed the second follow-up survey. SARS-CoV-2-positive participants were more likely to report fever at acute illness but were otherwise comparable to SARS-CoV-2-negative participants. At first follow-up, SARS-CoV-2-positive participants were less likely to have reported fully or mostly recovered from their illness compared to SARS-CoV-2-negative participants. At second follow-up, no differences by SARS-CoV-2 test results were detected in the four domains in the multivariable model. ConclusionSelf-reported disability was similar among outpatient SARS-CoV-2-positive and -negative adults 2-7 months after illness onset.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Clinical symptoms among ambulatory patients tested for SARS-CoV-2 96%
- Post-acute sequelae of SARS-CoV-2 (PASC) impact quality of life at 6, 12 and 18 months post-infection 94%
- High proportion of post-acute sequelae of SARS-CoV-2 infection in individuals 1-6 months after illness and association with disease severity in an outpatient telemedicine population 94%
Similar papers in this journal
- Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection 96%
- The association between prolonged SARS-CoV-2 symptoms and work outcomes 95%
- Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study 93%
Similar papers in this journal
- Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network 94%
- Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged ≥12 Years with Reported Contact with COVID-19 Cases, February – September 2021 94%
- The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers 94%
Similar papers in this journal
- Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics: A cross-sectional study 95%
- High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color 93%
- Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study 92%
Similar papers in this journal
- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February – May 2021 94%
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 94%
- Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.